Genus Capital Management’s ResMed RMD Stock Holding History

Genus Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,580	Closed	-$1.18M	–	223
2025 Q2	$1.18M	Buy	+4,580	New	+$1.09M	0.15%	127

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Genus Capital Management's RMD Position: Q3 2025 in Review

Genus Capital Management sold out of ResMed (RMD) in Q3 2025, closing a stake of 4,580 shares — an estimated $1.18M sold.

Genus Capital Management first reported a position in RMD in Q2 2025 and held it in 1 quarter. The position peaked at $1.18M in Q2 2025. 950 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

Genus Capital Management reported no remaining ResMed position as of Q3 2025 after selling out during the quarter.
Genus Capital Management sold 4,580 ResMed shares in Q3 2025, an estimated $1.18M.
Genus Capital Management first reported a position in ResMed in Q2 2025 and held it in 1 quarter.
Genus Capital Management's ResMed position peaked at $1.18M in Q2 2025.
950 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Genus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.